T2 Biosystms Company Overview
About T2 Biosystms
T2 Biosystems (NASDAQ:TTOO) is a company focused on innovative diagnostic solutions for critical health conditions. Their operations mainly revolve around the development and commercialization of diagnostic products that aim to save lives and improve patient outcomes by providing faster, more accurate detection of sepsis, Lyme disease, and other severe infections. Leveraging their proprietary T2 Magnetic Resonance technology, T2 Biosystems is dedicated to addressing challenges in healthcare where rapid and precise diagnostics are crucial. The company's objectives include expanding their product range, enhancing diagnostic efficiency, and making their technology accessible to a broader audience globally, ensuring that healthcare providers can make informed decisions swiftly, ultimately improving patient care.
Snapshot
Operations
Products and/or services of T2 Biosystms
- T2Dx Instrument, a fully automated device for rapid detection of pathogens and antibiotic resistance genes directly from whole blood samples.
- T2Bacteria Panel, identifies critical sepsis-causing bacteria directly from blood, avoiding culture delays.
- T2Candida Panel, detects five Candida species directly from blood, aiding in the rapid diagnosis of candidemia.
- T2Resistance Panel, identifies genetic markers of antibiotic resistance, facilitating targeted therapy choices.
- T2SARS-CoV-2 Panel, a molecular diagnostic test for the qualitative detection of SARS-CoV-2.
- T2Lyme Panel, an advanced diagnostic test for the detection of Lyme disease-causing bacteria.
T2 Biosystms executive team
- Mr. John J. Sperzel III, B.Sc.President, CEO & Chairman
- Mr. John M. Sprague CPAChief Financial Officer
- Mr. Michael Terrence Gibbs Esq.Senior VP, General Counsel & Company Secretary
- Ms. Kelley J. MorganChief People Officer
- Mr. Brett A. GiffinChief Commercial Officer
- Dr. Roger Smith Ph.D.Senior Vice President of Science Research & Development